Pretreatment serum endostatin as a prognostic indicator in metastatic gastric carcinoma
Corresponding Author
In Sook Woo
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Fax: 82-2-780-3132
Department of Internal Medicine, St. Mary's Hospital of the Catholic University, No. 62 Youido-dong, Youngdungpo-gu, Seoul 150-713, KoreaSearch for more papers by this authorKyung-Ae Kim
Catholic Research Institutes of Medical Science, Catholic University, Seoul, Korea
Search for more papers by this authorHae-Myung Jeon
Department of Surgery, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorSook Hee Hong
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorSang Young Rho
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorSu Jin Koh
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorMyung Ah Lee
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorJae Ho Byun
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorJin-Hyung Kang
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorYoung Seon Hong
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorKyung Shik Lee
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorChul-Soo Cho
Division of Rheumatology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorMyung Gyu Choi
Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorIn-Sik Chung
Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorCorresponding Author
In Sook Woo
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Fax: 82-2-780-3132
Department of Internal Medicine, St. Mary's Hospital of the Catholic University, No. 62 Youido-dong, Youngdungpo-gu, Seoul 150-713, KoreaSearch for more papers by this authorKyung-Ae Kim
Catholic Research Institutes of Medical Science, Catholic University, Seoul, Korea
Search for more papers by this authorHae-Myung Jeon
Department of Surgery, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorSook Hee Hong
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorSang Young Rho
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorSu Jin Koh
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorMyung Ah Lee
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorJae Ho Byun
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorJin-Hyung Kang
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorYoung Seon Hong
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorKyung Shik Lee
Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorChul-Soo Cho
Division of Rheumatology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorMyung Gyu Choi
Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorIn-Sik Chung
Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Catholic University, Seoul, Korea
Search for more papers by this authorAbstract
Endostatin is the C-terminal antiangiogenic fragment of the extracellular matrix protein collagen XVIII, and is generated by tumor-derived proteases. The presence of serum endostatin in patients with gastric cancer has not been reported. The authors assessed the serum levels of endostatin in patients with gastric carcinoma and evaluated their association with the levels of vascular endothelial growth factor (VEGF) and the clinical outcome. A total of 107 patients with gastric cancer were included in the study. Pretherapeutic serum levels of endostatin and VEGF were measured using an ELISA, and compared with those in 23 healthy controls. The serum levels of endostatin and VEGF were higher in gastric cancer patients than in healthy controls (endostatin, 70.1 ± 16.6 vs. 52.2 ± 6.2 ng/mL [p < 0.001]; VEGF, 55.1 ± 7.6 vs. 32.1 ± 2.4 ng/mL [p < 0.001]; mean ± SD). Serum endostatin levels were significantly associated with the presence of distant metastases (r = 0.556, p < 0.001) and VEGF levels (r = 0.335, p < 0.001), but not with the depth of tumor invasion, differentiation, or regional lymph node status. A serum endostatin level above the 75th percentile of the distribution for the patients (79.2 ng/mL) was associated with a poor outcome (last follow-up at 42 months; median survival time, 9 vs. 20 months [log-rank, p = 0.017]; median time to progression, 5 vs. 10 months [log-rank, p = 0.022]) in the patients with metastatic gastric cancer. The results suggest for the first time that an elevated serum level of endostatin at the diagnosis of metastatic gastric cancer could be predictive of a poor outcome. © 2006 Wiley-Liss, Inc.
References
- 1 Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000; 19: 1187–94.
- 2 Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000; 486: 247–51.
- 3 Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J. The generation of endostatin is mediated by elastase. Cancer Res 1999; 59: 6052–6.
- 4 O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–85.
- 5 Saarela J, Rehn M, Oikarinen A, Autio-Harmainen H, Pihlajaniemi T. The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol 1998; 153: 611–26.
- 6 Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, Benjamin LE, Lawler J, Kieran M, Shah A, Kalluri R. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 2005; 102: 2934–9.
- 7 Feldman AL, Alexander HR,Jr, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 2002; 95: 1637–43.
- 8 Bono P, Teerenhovi L, Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 2003; 97: 2767–75.
- 9 Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Turner EM, Alexander HR,Jr, Libutti SK. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 2000; 6: 4628–34.
- 10 Konno H, Ohta M, Baba M, Suzuki S, Nakamura S. The role of circulating IL-8 and VEGF protein in the progression of gastric cancer. Cancer Sci 2003; 94: 735–40.
- 11 Ohta M, Konno H, Tanaka T, Baba M, Kamiya K, Syouji T, Kondoh K, Watanabe M, Terada H, Nakamura S. The significance of circulating vascular endothelial growth factor (VEGF) protein in gastric cancer. Cancer Lett 2003; 192: 215–25.
- 12 Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Kim HK, Ryu KW, Bae JM, Kim S. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003; 39: 184–91.
- 13 Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236: 37–42.
- 14 Han GS, Park YK, Chi KC, Park SJ, Lim HM, Park SI, Park US. Prognostic significance of VEGF in human stomach cancer. Cancer Res Treat 1999; 31: 1087–93.
- 15 Hu TH, Huang CC, Wu CL, Lin PR, Liu SY, Lin JW, Chuang JH, Tai MH. Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma. Mod Pathol 2005; 18: 663–72.
- 16 Clamp AR, Jayson GC. The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br J Cancer 2005; 93: 967–72.
- 17 Iizasa T, Chang H, Suzuki M, Otsuji M, Yokoi S, Chiyo M, Motohashi S, Yasufuku K, Sekine Y, Iyoda A, Shibuya K, Hiroshima K, et al. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res 2004; 10: 5361–6.
- 18 Suzuki M, Iizasa T, Ko E, Baba M, Saitoh Y, Shibuya K, Sekine Y, Yoshida S, Hiroshima K, Fujisawa T. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002; 35: 29–34.
- 19
Feldman AL,
Pak H,
Yang JC,
Alexander HR,Jr,
Libutti SK.
Serum endostatin levels are elevated in patients with soft tissue sarcoma.
Cancer
2001;
91:
1525–9.
10.1002/1097-0142(20010415)91:8<1525::AID-CNCR1161>3.0.CO;2-P CAS PubMed Web of Science® Google Scholar
- 20 Feldman AL, Alexander HR,Jr, Bartlett DL, Kranda KC, Miller MS, Costouros NG, Choyke PL, Libutti SK. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol 2001; 8: 741–5.
- 21 Folkman J. Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594–607.
- 22 Tjin Tham Sjin RM, Satchi-Fainaro R, Birsner AE, Ramanujam VM, Folkman J, Javaherian K. A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res 2005; 65: 3656–63.
- 23 Celik I, Surucu O, Dietz C, Heymach JV, Force J, Hoschele I, Becker CM, Folkman J, Kisker O. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 2005; 65: 11044–50.
- 24 Nyberg P, Heikkila P, Sorsa T, Luostarinen J, Heljasvaara R, Stenman UH, Pihlajaniemi T, Salo T. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem 2003; 278: 22404–11.
- 25 Eder JP,Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002; 20: 3772–84.
- 26 Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20: 3792–803.
- 27 Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003; 21: 223–31.
- 28 Zhao J, Yan F, Ju H, Tang J, Qin J. Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett 2004; 204: 87–95.
- 29 Unemori EN, Ferrara N, Bauer EA, Amento EP. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992; 153: 557–62.
- 30
Zucker S,
Mirza H,
Conner CE,
Lorenz AF,
Drews MH,
Bahou WF,
Jesty J.
Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation.
Int J Cancer
1998;
75:
780–6.
10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.0.CO;2-A CAS PubMed Web of Science® Google Scholar
- 31 Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, Figg WD, Albert PS, Menard C, Camphausen K. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 2004; 22: 499–506.
- 32 Klement G, Kikuchi L, Kieran M, Almog N, Tung Yip T, Folkman J. Early tumor detection using platelet uptake of angiogenesis regulators. Blood 2004; 104: 239a (abstract no. 833).
Citing Literature
